Krka presented its operating results for the first half of 2016

Krka Group sales by Region

Sales in Krka’s domestic market were up 6% to €41.2 million, which is 6.8% of Group sales. Holding a 9.3% market share, Krka remains the leading pharmaceutical company in Slovenia.

The highest relative as well as absolute sales growth, of 27%, or €16.3 million, was recorded in Region South-East Europe, where sales totalled €76.8 million, which represents 12.7% of Group sales. Sales growth was recorded in all markets in the Region, apart from Montenegro, with the largest market contributor in absolute terms being Romania.

Krka’s largest sales region was Region East Europe, where sales totalled €175.5 million, which is 29.1% of Group sales. Sales in this Region were down 6% compared to the same period last year.

The second largest region in terms of sales was West Europe, where Krka generated €150.4 million of sales (down 8%), which represents 24.9% of Group sales. Despite sales volume up 14%, decreasing prices caused the value of sales to drop.

Product sales in Region Central Europe represented 23.4% of Group sales. The volume of sales was up 6% and the value of sales up 3% to €141.4 million. Sales value growth was recorded in all markets in the Region, apart from Lithuania.

Six-month product sales in Region Overseas Markets totalled €18.5 million (25% increase), which represents 3.1% of Group sales. The majority of sales, 88%, came from prescription pharmaceuticals, which are sold under Krka’s own brands in most of the Region’s markets.

Krka Group sales by product and service group

The Krka Group sold €499.4 million worth of prescription pharmaceuticals, down 2% compared to the same period last year. The volume of sold prescription pharmaceuticals increased by 12%, and the value of sales was also up in regions South-East Europe (up 29%), Overseas Markets (up 23%), Central Europe (up 1%) and Slovenia (up 1%). Prescription pharmaceuticals represent 82.7% of Krka Group sales.

The ten leading prescription pharmaceuticals in terms of sales are Atoris (atorvastatin), Lorista (losartan), Nolpaza (pantoprazole), Prenessa (perindopril), Enap (enalapril), Valsacor (valsartan), Emanera (esomeprazole), Roswera (rosuvastatin), Zyllt (clopidogrel) and Dulsevia (duloxetine). These products may appear under different brand names in individual markets.

For non-prescription products, sales value was down 1% compared to the same period last year, to €50.3 million (8.3% of Group sales), however sales volume was up 4%. The sales of animal health products were up 44% to €37.3 million, which is 6.2% of Group sales. Health resort and tourist services totalled €15.4 million in sales revenues, up one tenth from the same period last year (2.6% of Group sales).

Research and development

In the first half of 2016 Krka was granted marketing authorisations for three new products and it obtained 170 new marketing authorisations in different markets, with which they expanded marketing opportunities for products from different indication groups.

Investments

In the first half of 2016 the Krka Group allocated €61.8 million to investments, of which the controlling company invested €30 million and subsidiaries €31.8 million.

Employees

At the end of June the Krka Group had 10,821 employees, which is 257 or 2.4% more than at the beginning of the year. 54% of Krka Group employees work outside Slovenia, and 56% of the entire Krka team have at least a university-level qualifications.